Media coverage about CytomX Therapeutics (NASDAQ:CTMX) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.4518154339531 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities analysts recently commented on CTMX shares. Jefferies Group LLC restated a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a report on Wednesday, April 26th. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a report on Wednesday, May 3rd. HC Wainwright restated a “buy” rating on shares of CytomX Therapeutics in a report on Monday, May 8th. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Finally, Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $24.50.

Shares of CytomX Therapeutics (CTMX) traded up 0.22% during trading on Monday, hitting $13.65. The company had a trading volume of 103,698 shares. The company’s market capitalization is $501.62 million. The stock’s 50-day moving average price is $14.72 and its 200 day moving average price is $14.43. CytomX Therapeutics has a 52 week low of $9.84 and a 52 week high of $20.02.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.32. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. The company had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $2.10 million. On average, equities research analysts forecast that CytomX Therapeutics will post ($1.41) earnings per share for the current year.

In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $15.47, for a total value of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 22,126 shares in the company, valued at approximately $342,289.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Robert I. Tepper sold 15,000 shares of the company’s stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $16.00, for a total value of $240,000.00. Following the completion of the sale, the insider now owns 44,777 shares of the company’s stock, valued at $716,432. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,062 shares of company stock valued at $497,641. 8.00% of the stock is owned by company insiders.

WARNING: “CytomX Therapeutics (NASDAQ:CTMX) Receiving Somewhat Positive News Coverage, Analysis Finds” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/cytomx-therapeutics-nasdaqctmx-receiving-somewhat-positive-news-coverage-analysis-finds.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.